Recapitulation of EGFR mutations in lung cancer cells in vitro have demonstrated that it is an example of an 'oncogenic addiction' mutation which provides a biologic explanation for the improved outcome seen in this EGFR mutant NSCLC group relative to the wild type group[9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.